Trial Information: 37 patients over 70 years old are being recruited for a Phase II study of ofatumumab (Arzerra). Patients will be given weekly ofatumumab for eight weeks.
Eligible patients must have indolent lymphoma (follicular lymphoma or marginal zone lymphoma) and be previously untreated.
Background Information: Ofatumumab is a new humanized anti-CD20 monoclonal antibody, similar to the better-known rituximab but based on a fully human protein rather than a chimeric mouse-antibody protein. There are a number of ongoing trials aimed at assessing the effectiveness of this drug.
Thus far it appears to have only marginal effectiveness in patients who have relapsed or become resistant to rituximab, but may be much more promising in the first-line, pre-rituximab setting. In this setting it would be presumably at least as effective, and potentially more effective, than rituximab, and possibly with fewer side effects or allergic reactions.
Trial Locations: United States (North Carolina)
For more information, see ClinicalTrials.gov.
Ofatumumab is a CD20-directed cytolytic monoclonal antibody with an inhibitory effect on early-stage B lymphocyte. It was approved by FDA for its use to treat patients with chronic lymphocytic leukemia (CLL) as an extended treatment or in combination with chlorambucil. Ofatumumab
ReplyDelete